Probudur (liposomal bupivacaine) / Virpax Pharma - LARVOL DELTA

EL012: A Novel Safe, Potent and Ultra-Long-Acting Non-Opioid Post-Surgical Analgesic Candidate (IASP 2024) - "Although a few long-acting sustained-release formulations containing Bupivacaine (Bu) have been approved (Exparel® and its generic drug Aihengping(AHP, CHN brand ???®)) or in research (Probudur), their analgesic duration is notably behind the time of 30 days expected by FDA... EL012 hydrochloride and positive controls (Bu, Levobupivacaine(LBu)) were dissolved in normal saline to prepare different concentrations of solutions, and their analgesic effects were evaluated in Hartley guinea pigs and SD rats, by defining the inhibition of the cutaneous trunci muscle reflex in pin-prick (PP) tests after subcutaneous (SC) injections of 0.6 ml solutions... Our studies show that the newly designed EL012 has a much longer local retention time, and long-acting analgesic duration to be 48 times longer than Bu and LBu after SC administration in guinea pigs and rats. The same locally administered EL012 has a 32 times longer analgesic duration than AHP, a long-acting..."

Addiction (Opioid and Alcohol) • Anesthesia • Cardiovascular • CNS Disorders • Pain • Psychiatry • NAV1

"$VRPX Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™ https://t.co/QZRxiQTGAB" (@stock_titan)

"$VRPX Virpax Announces Results of Probudur(TM) in Animal Study https://t.co/frG51VRxBR" (@stock_titan)

"$VRPX Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Probudur(TM) for Postoperative Pain https://t.co/blNl6iHgMz" (@stock_titan)

IND • Pain

Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM) (Virpax Pharma Press Release) - "Virpax Pharmaceuticals...today announced that the United States Patent and Trademark Office issued US Patent No. 10842745 entitled, 'Composition of matter comprising liposome embedded in a polymerix matrix and methods of using same.'This newly issued patent, which is owned by LipoCure Rx and exclusively licensed to Virpax, has 18 claims and expires in 2029. The patent covers a liposomal composition containing bupivacaine as well as additional claims covering methods for providing analgesia in patients by administration of the liposomal compositions."

Patent • Pain